This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
A recent Phase III clinical trial, TRIUMPH-2, evaluated the efficacy and safety of retatrutide, a triple receptor agonist and experimental once-weekly injection being developed to treat obesity and type 2 diabetes. What sets it apart from drugs such as semaglutide (Wegovy), which targets one hormone, and tirzepatide (Zepbound), which targets two, is its ability to activate three hormone receptors at once.
Developed by Eli Lilly, retatrutide mimics GLP-1, which lowers blood sugar and promotes fullness, and GIP, which enhances the body's insulin response and helps reduce body weight alongside GLP-1. It also activates glucagon receptors, adding a third mechanism that increases energy expenditure and metabolic activity, helping the body burn more energy.
After 80 weeks of once-weekly injections, 1,152 adults living with both obesity and type 2 diabetes saw major changes on the scale. Those on the highest dose lost an average of 18.8% of their body weight, roughly 20.7 kg (about 45.5 pounds), compared with 5.1% in the placebo group. The loss was even bigger for those who started with a BMI of 35 or higher, who lost an average of 21.9% of their body weight on the 12 mg dose.
Weight loss isn't always about meeting existing beauty standards. It can be medically necessary, since weight gain is linked to many metabolic and cardiovascular conditions. Studies show that even a modest weight loss of 5–10% can lower both systolic and diastolic blood pressure and raise good cholesterol.
Source link
